X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs IPCA LABS - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA IPCA LABS SANOFI INDIA/
IPCA LABS
 
P/E (TTM) x 33.7 42.1 80.1% View Chart
P/BV x 6.4 3.2 198.9% View Chart
Dividend Yield % 1.4 0.2 882.5%  

Financials

 SANOFI INDIA   IPCA LABS
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
IPCA LABS
Mar-17
SANOFI INDIA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs4,560643 709.2%   
Low Rs4,400503 875.1%   
Sales per share (Unadj.) Rs1,028.5254.4 404.3%  
Earnings per share (Unadj.) Rs129.016.1 802.5%  
Cash flow per share (Unadj.) Rs186.029.8 624.6%  
Dividends per share (Unadj.) Rs68.001.00 6,800.0%  
Dividend yield (eoy) %1.50.2 869.6%  
Book value per share (Unadj.) Rs753.6194.6 387.4%  
Shares outstanding (eoy) m23.03126.20 18.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.42.3 193.4%   
Avg P/E ratio x34.735.7 97.4%  
P/CF ratio (eoy) x24.119.2 125.2%  
Price / Book Value ratio x5.92.9 201.9%  
Dividend payout %52.76.2 847.3%   
Avg Mkt Cap Rs m103,17472,300 142.7%   
No. of employees `0003.613.3 27.2%   
Total wages/salary Rs m3,5926,960 51.6%   
Avg. sales/employee Rs Th6,537.72,413.5 270.9%   
Avg. wages/employee Rs Th991.4523.2 189.5%   
Avg. net profit/employee Rs Th819.8152.4 537.7%   
INCOME DATA
Net Sales Rs m23,68632,106 73.8%  
Other income Rs m708226 313.7%   
Total revenues Rs m24,39432,332 75.4%   
Gross profit Rs m5,2814,448 118.7%  
Depreciation Rs m1,3131,730 75.9%   
Interest Rs m15241 6.2%   
Profit before tax Rs m4,6612,703 172.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,691675 250.4%   
Profit after tax Rs m2,9702,028 146.4%  
Gross profit margin %22.313.9 160.9%  
Effective tax rate %36.325.0 145.2%   
Net profit margin %12.56.3 198.5%  
BALANCE SHEET DATA
Current assets Rs m15,67317,340 90.4%   
Current liabilities Rs m6,6789,559 69.9%   
Net working cap to sales %38.024.2 156.7%  
Current ratio x2.31.8 129.4%  
Inventory Days Days76100 75.8%  
Debtors Days Days2257 39.2%  
Net fixed assets Rs m8,09820,779 39.0%   
Share capital Rs m230252 91.2%   
"Free" reserves Rs m17,08824,499 69.8%   
Net worth Rs m17,35624,553 70.7%   
Long term debt Rs m03,517 0.0%   
Total assets Rs m25,40039,595 64.1%  
Interest coverage x311.712.2 2,549.8%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.90.8 115.0%   
Return on assets %11.85.7 205.1%  
Return on equity %17.18.3 207.2%  
Return on capital %26.910.5 256.9%  
Exports to sales %24.548.6 50.3%   
Imports to sales %28.014.2 196.5%   
Exports (fob) Rs m5,80115,617 37.1%   
Imports (cif) Rs m6,6274,571 145.0%   
Fx inflow Rs m7,14515,617 45.8%   
Fx outflow Rs m6,8465,828 117.5%   
Net fx Rs m2999,790 3.1%   
CASH FLOW
From Operations Rs m3,2262,764 116.7%  
From Investments Rs m-1,555-1,432 108.6%  
From Financial Activity Rs m-1,818-1,591 114.2%  
Net Cashflow Rs m-147-259 56.8%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 11.4 126.3%  
FIIs % 14.6 25.3 57.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.4 60.3%  
Shareholders   15,184 36,892 41.2%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   ALEMBIC LTD  SUN PHARMA  PFIZER  FDC LTD.  AUROBINDO PHARMA  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 20, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - SUN PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS